Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 16, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details within the SmithKline Beecham Employee Benefit Trust.
Material Changes
The filing details specific share movements in early January 2007:
- January 11, 2007: 38,040 Ordinary shares were transferred from the Trust to a participant in the SmithKline Beecham Annual Investment Plan.
- January 12, 2007: The Trust acquired 380 Ordinary shares at GBP 13.70 per share following dividend re-investment for the Bonus Investment Plan.
- January 12, 2007: The Trust acquired 9,668 Ordinary shares at GBP 13.70 per share following dividend re-investment for the Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J S Heslop holds an interest in the fund shares similarly to other beneficiaries.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following these transactions.
- Confirm the impact of the GBP 13.70 share price on the Trust's valuation relative to market prices on the transaction dates.
- Review the specific terms of the SmithKline Beecham Annual Investment Plan and Bonus Investment Plan to understand the mechanics of the dividend re-investments.